Verrica Pharmaceuticals (VRCA) Competitors $0.48 -0.01 (-2.88%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. TERN, FHTX, ESPR, OCGN, AMRN, BTMD, SOPH, CRDF, GOSS, and DSGNShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Terns Pharmaceuticals (TERN), Foghorn Therapeutics (FHTX), Esperion Therapeutics (ESPR), Ocugen (OCGN), Amarin (AMRN), biote (BTMD), SOPHiA GENETICS (SOPH), Cardiff Oncology (CRDF), Gossamer Bio (GOSS), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Terns Pharmaceuticals Foghorn Therapeutics Esperion Therapeutics Ocugen Amarin biote SOPHiA GENETICS Cardiff Oncology Gossamer Bio Design Therapeutics Terns Pharmaceuticals (NASDAQ:TERN) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Which has higher earnings and valuation, TERN or VRCA? Verrica Pharmaceuticals has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$90.21M-$1.13-2.00Verrica Pharmaceuticals$7.57M5.68-$67M-$1.54-0.30 Does the MarketBeat Community favor TERN or VRCA? Verrica Pharmaceuticals received 125 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 63.26% of users gave Verrica Pharmaceuticals an outperform vote while only 59.15% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTerns PharmaceuticalsOutperform Votes4259.15% Underperform Votes2940.85% Verrica PharmaceuticalsOutperform Votes16763.26% Underperform Votes9736.74% Is TERN or VRCA more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Terns Pharmaceuticals' return on equity of -32.76% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -32.76% -31.33% Verrica Pharmaceuticals -625.06%-591.84%-141.63% Do insiders and institutionals hold more shares of TERN or VRCA? 98.3% of Terns Pharmaceuticals shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 15.1% of Terns Pharmaceuticals shares are held by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer TERN or VRCA? Terns Pharmaceuticals currently has a consensus target price of $18.38, indicating a potential upside of 713.05%. Verrica Pharmaceuticals has a consensus target price of $9.50, indicating a potential upside of 1,928.61%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer TERN or VRCA? In the previous week, Verrica Pharmaceuticals had 10 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 13 mentions for Verrica Pharmaceuticals and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 1.11 beat Verrica Pharmaceuticals' score of 0.28 indicating that Terns Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TERN or VRCA? Terns Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. SummaryVerrica Pharmaceuticals beats Terns Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.98M$6.30B$5.32B$7.42BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.266.7721.7317.75Price / Sales5.68222.97372.3693.57Price / CashN/A65.6738.1534.64Price / Book1.005.806.393.97Net Income-$67M$142.23M$3.20B$247.37M7 Day Performance1.17%3.39%2.11%1.02%1 Month Performance-12.84%-13.52%-9.13%-6.65%1 Year Performance-93.31%-12.08%9.92%0.06% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.0063 of 5 stars$0.48-2.9%$9.50+1,882.5%-92.9%$43.98M$7.57M-0.2640Short Interest ↑TERNTerns Pharmaceuticals4.0198 of 5 stars$2.31+7.9%$18.38+695.5%-52.6%$201.66MN/A-1.9640Positive NewsFHTXFoghorn Therapeutics2.2289 of 5 stars$3.59+4.1%$13.17+266.8%-44.1%$199.65M$22.60M-1.87120News CoverageGap DownESPREsperion Therapeutics3.6647 of 5 stars$1.00-2.0%$6.58+558.9%-48.5%$197.67M$332.31M-1.56200OCGNOcugen1.0157 of 5 stars$0.67-2.8%$6.33+843.4%-56.1%$196.03M$4.06M-3.7380Gap DownAMRNAmarin0.2123 of 5 stars$9.47+1.8%N/A-46.6%$194.46M$228.61M-105.22360Analyst ForecastHigh Trading VolumeBTMDbiote3.3611 of 5 stars$3.53-3.3%$8.00+126.6%-41.4%$193.13M$197.19M13.58194Positive NewsGap DownSOPHSOPHiA GENETICS1.94 of 5 stars$2.89+0.3%$6.80+135.3%-42.2%$192.73M$65.17M-2.65520Positive NewsGap DownCRDFCardiff Oncology1.1812 of 5 stars$2.79+13.0%$11.67+318.2%-44.3%$185.60M$683,000.00-2.9720News CoverageGap UpGOSSGossamer Bio3.7733 of 5 stars$0.81-1.5%$7.75+853.4%-3.3%$184.71M$114.70M-2.54180Short Interest ↑DSGNDesign Therapeutics1.89 of 5 stars$3.25+12.5%$8.00+146.2%-12.4%$184.48MN/A-3.8240Gap Down Remove Ads Related Companies and Tools Related Companies TERN Alternatives FHTX Alternatives ESPR Alternatives OCGN Alternatives AMRN Alternatives BTMD Alternatives SOPH Alternatives CRDF Alternatives GOSS Alternatives DSGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
